Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm’s broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of our clients.
The firm is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Our services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, and employee benefits and employment law, among other areas. Our distinguished international roster of clients span a wide variety of industries, including information technology, life sciences, energy and clean technology, media and entertainment, communications, retail, and financial services.
Suzhou BioBAY is the key driver of life science innovation for Suzhou Industrial Park (SIP). Nearly 500 high-tech innovative companies covering drug discovery, medical device (including IVD), biotech, CRO have been located in BioBAY. More than 10000 scientists and professionals have come to join this dynamic innovative community.
BioBAY is playing an active role in building an interactive and collaborative innovation ecosystem:
- Cold Spring Harbor Asia Conference Centre — cutting-edge academic resources and global technical communication
- BioTOP — one-stop professional solutions for biomedical companies, including analysis & test, GMP verification, biomaterials trading, training, etc.
- BioBAY Sangtian Island — commercialization base for high-tech drug, medical device and IVD companies
- BioBAY Changshu — top class industrial base for biomedical industry with international advanced standards
6 Dimensions Capital is a leading healthcare focused investment firm with an in-depth focus and extensive coverage across China and the United States. The firm currently has US$2.3 billion assets under management through 4 US dollar-denominated and 4 RMB-denominated funds with offices in Shanghai, Boston, Hong Kong and San Francisco.
6 Dimensions Capital was formed in May 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures, two prominent and complementary China-U.S. healthcare investment firms. The merger has created a powerhouse that aims to fund innovation in an optimal position to capture the biggest value appreciation on both sides of the Pacific.
Eight Roads Ventures is a global venture capital firm that backs entrepreneurs with aspirations for greatness.It has over 20 years of venture capital experience in China and has supported over 80 companies in the country’s healthcare, enterprise technology, Fintech and consumer technology sectors. As the proprietary investment arm of Fidelity International Limited, Eight Roads is committed to building bold and meaningful businesses. Including its associated funds, it has offices in China, Japan, UK, India and the US.
Eight Roads Ventures led successful investments in China, including Alibaba, China PnR, Wuxi PharmaTech, Hile, Innovent, Adagene and Hua Medicine. It launched its first USD 250 m China Healthcare Fund in 2017.
Bio2 was founded in 2019 in Beijing, China. Bio2’s mission is to fix life science innovation by developing total solutions that support biotech startups during their entrepreneurial exploration. We not only provide physical space with well-furnished flexible offices, well-equipment shared wet lab facilities, and targeted programming, where companies of all sizes, stages can build their businesses and connect with one another. Moreover, we put our efforts on creating a physical center of gravity for the local innovation ecosystem, delivering innovation clusters in future-focused area to catalyze existing resources and generate growth.
Morgan Stanley (NYSE: MS) is a leading global financial services firm providing investment banking, securities, wealth management and investment management services. With offices in more than 41 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For more information about Morgan Stanley, please visit www.morganstanley.com.
Nan Fung Life Sciences, a global life sciences investment platform with a long-term capital commitment from the Nan Fung Group. The team possesses diverse experience with long track records in company formation, venture capital, growth/buyout investments, and drug discovery and development. Through direct investments via Pivotal BioVenture Partners US and Pivotal BioVenture Partners China as well as fund investments, NFLS cover the full spectrum of the life sciences industry including therapeutics, medical devices, and diagnostics and across all development stages.
Pivotal bioVenture Partners China, a member of Nan Fung Life Sciences, is a venture capital firm specializing in venture building in the life sciences industry. Its investment strategy is centered on identifying promising innovative products and technologies and bringing them to serve the growing unmet medical needs in Greater China region by building new ventures. Its investment areas include therapeutics, medical devices and medical services. The Pivotal China team includes experienced life science investors and entrepreneurs with successful track records of venture building and investing.
Pfizer is proud of its long history of successfully partnering with external organizations that share in our purpose to deliver breakthroughs that change patients’ lives. We engage in partnerships with innovators to push forward great science and continually seek new partners that are actively researching bold scientific ideas, capabilities and technologies that have the potential to bring innovative treatments to patients in need.
The UK’s Department for International Trade (DIT) has overall responsibility for promoting UK trade across the world and attracting foreign investment to our economy. We are a specialized government body with responsibility for negotiating international trade policy, supporting business, as well as delivering an outward-looking trade diplomacy strategy. UK offers one of the strongest and most productive life sciences sectors in the world with a high concentration of talent and ample opportunities for value creation through partnering, deal-making or investment. DIT supports and facilitates UK and China life science collaboration in cross border licensing, investment, services and distribution.
Intralinks, an SS&C company, is a leading financial technology provider for the global dealmaking, alternative investments and capital markets communities. As pioneers of the virtual data room, our technology enables and secures the flow of information, empowering our customers to work more productively and with complete confidence. Intralinks facilitates strategic initiatives such as mergers and acquisitions, corporate lending, debt sales, capital raising and investor reporting. Our solutions enhance these activities by streamlining operations, reducing risk, improving client experiences and increasing visibility. We’ve earned the trust and business of more than 99 percent of the Global Fortune 500 and have executed over $35 trillion in financial transactions on our platform.
Established in 1989, OrbiMed is healthcare and life sciences-dedicated investment firm across the globe. OrbiMed manages approximately USD$16 billion assets and has invested in over 300 private companies across a wide range of therapeutic categories and stages of development, over 100 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well. OrbiMed Asia, with offices in Shanghai and Mumbai, has established one of the first pan-Asia healthcare-dedicated PE/VC funds. With over USD$1 billion under management, it has made investments in over 50 companies.
Sanofi is a leading global biopharmaceutical company focused on human health. In 1982, Sanofi opened an office in China as one of the first multinational corporations to support China’s opening up and reform. Sanofi China has a diversified business that ranges from pharmaceuticals and human vaccines to consumer healthcare. We have 12 offices, 3 production sites, 4 R&D sites and 1 digital innovation hub in China. Sanofi is committed to introducing innovative medicines and vaccines faster in China, and leading digital innovations to serve the broadest base of the Chinese people.
BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.
Our mission is simple: create the best, most innovative events to provide you with the latest business information and the greatest opportunity to network with your peers and new potential business partners.
Since 2008, Lychee Group has helped launch some of the longest running and most reputable life sciences conferences in China including: ChinaTrials: Clinical Development Leaders' Summit, China Healthcare Investment Conference (CHIC), China Medical Affairs Summit, DeviceChina, BioCentury's China Healthcare Summit and Healthcare Capital & Connections Summit (HCCS).
Since our founding in January, 2007, ChinaBio® Group has successfully helped nearly 100 US, European and Asia-Pacific life science companies achieve success in China. Leveraging our consulting and advisory teams' significant experience in China's life science industry, and our extensive proprietary databases, we have helped our clients identify over 1,400 in-/out- licensing and M&A opportunities and raise over $500M in funding in China. Our clients have included many global pharma and life science companies as well as early stage and mid-size companies. ChinaBio® Group is headquartered in Shanghai with offices in San Diego, Silicon Valley and Basel, Switzerland
Conferences: ChinaBio® has organized over 30 premier life science investment and partnering conferences in China, the US and Europe. Our premier event, ChinaBio® Partnering Forum, attracts over 1200 industry executives to China from around the world each spring.
Consulting: ChinaBio helps global life science companies to define and execute a successful strategy in China.
Capital: ChinaBio® has helped US and EU companies raise over $500M in China. Our advisory practice works with more than 30 major VCs and strategic investors in China to fund companies with novel technologies and products.
Publishing: ChinaBio Today (www.ChinaBioToday.com) is the most widely read online and email newsletter on China's life science industry, with over 18,000 readers.
Founded in Shanghai in 2002, GBI has built a diverse portfolio of market intelligence solutions for pharmaceutical and device companies and other service providers. Focused on China and the Latin American markets, GBI’s value-added industry information, news, and data services power individuals and organizations’ decision-making and enable more effective communication. As a trusted source of information, GBI has established long-term relationships with both multinational players and local firms, and continues to drive forward the health care industry.
GBI has offices in Shanghai, Beijing, and Washington D.C.
GlobalData is a leading data analytics, market research and consulting service company listed on the London Stock Exchange with over 3000 staff and 23 offices around the globe. We serve over 4,000 world’s largest companies with over 600 healthcare analysts by gaining insights into competitors, evaluating market opportunities, and provide strategic opinions in pharmaceutical, biotechnological and medical devices industries. From research and development, clinical trials, business developments to investment due diligence, our clients can make better business decisions on our fully integrated one-stop intelligence center platform.
Lingmed is a young, professional and fast growing company, it promotes world best in class intelligence databases to healthcare industry and provide with its premium services – Linkedbio - which provides analytical services and reports to help our clients to make better decisions and support BD sourcing activities.
Cofounded by experienced journalists and editors in 2014, PharmaDJ is the leading business intelligence and media portal for Pharmaceutical and Biotech industry in China. Since then, it has built a wide platform to serve the industry need. Now, it provides different services including business intelligence, business strategy consulting and conference/training program to its readers and clients. With the editorial team located in Shanghai, Guangzhou, Beijing, Suzhou, New Jersey and Hawii, our focus covers the entire drug life cycle, from early drug research, translational science, clinical development, commercial, market access and PR communication strategies. Every day, our voice reaches thousands of industry executives, investors and regulators through our multi-media platforms that consist of website, WeChat, Xueqiu, Toutiao, LinkedIn and more. With the mission to become the lighthouse for the Chinese pharmaceutical industry, we will continue our journey to facilitate the development of pharmaceutical industry.